Both ketosis and GLP-1 medications alter nutrient availability and metabolic function in ways that could affect fetal development or milk production
R.CarrV
That's why we monitor all our patients closely to ensure success across all our programs
A recent AMA/CDC report covered the challenges with long term adherence and the introduction of new indications will drive the need for ongoing research incorporating richer data sources beyond claims
Interpretation of Efficacy and Safety Findings At study completion, 83% of GLP-1RA users and 67% of metformin users achieved the target HbA1c of 48 mmol/mol
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
